IRAK-4 targeting therapeutic (Beijing Hanmi Pharmaceutical)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameIRAK-4 targeting therapeutic (Beijing Hanmi Pharmaceutical)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 modulators
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesBeijing Hanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Hanmi Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A